rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Akari Therapeutics Plc - American Depositary Shares

AKTX · Nasdaq

Health CareBiotechnologyNot moving yet

AKTX stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 1.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
8 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$36KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0
WhoDidSharesTraded
James R. NealDirectorbought2,47316 Dec 2025filed 16 Mar 2026
James R. NealDirectorbought2,473at $0.404116 Dec 2025filed 16 Mar 2026
James R. NealDirectorbought3,09316 Dec 2025filed 16 Mar 2026
James R. NealDirectorbought3,093at $0.404116 Dec 2025filed 16 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders8+3 on the quarter
New · exited4 · 2
Reported value$1.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MMCAP International Inc. SPCnew · filed 14 Aug 2026100,000$1.0M+100,000
Cresset Asset Management, LLCunchanged · filed 14 Aug 202620,561$211K00.0%
JANE STREET GROUP, LLCnew · filed 14 Aug 202615,463$158K+15,463
SBI Securities Co., Ltd.added · filed 23 Jul 202614$143+9+180.0%
Caitong International Asset Management Co., Ltdnew · filed 5 Aug 20268$82+8
NORTHWESTERN MUTUAL WEALTH MANAGEMENT COnew · filed 12 Aug 20267$72+7
Truvestments Capital LLCunchanged · filed 12 Aug 20261$1000.0%
30 Sep 2023 – 30 Jun 2026
61320Sep 23Jun 24Mar 25Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Abizer Gaslightwala Company insiderCEO · last 14 Oct 20267 · 0
Robert B. Bazemore Company insiderDirector · last 14 Oct 20260 · 0
Sandip I. Patel Company insiderDirector · last 14 Oct 20260 · 0
Vatnak Vat-Ho Company insiderChief Business Officer · last 12 Oct 20260 · 0
Hoyoung Huh Company insiderDirector, 10% owner · last 5 Oct 20260 · 0
Raymond Prudo-Chlebosz Company insiderDirector · last 5 Oct 20260 · 0
Samir Rashmikant Patel Company insiderDirector · last 5 Oct 20260 · 0
Kameel D. Farag Company insiderInterim CFO · last 17 Aug 20260 · 0
James R. Neal Company insiderDirector · last 16 Dec 20250 · 0
Torsten Hombeck Company insiderCFO · last 20 Mar 20250 · 0
Donald A. Williams Company insiderDirector · last 28 Jun 20240 · 0
Michael Grissinger Company insiderDirector · last 28 Jun 20240 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-48.6%
Share count trendFY 2025 · to 1 Mar 20261.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$0

Analyst forecasts

No analyst forecasts yet.